FDC Limited

FDC Limited (India) holds 17 active US FDA Type II Drug Master Files and 12 inactive, has DMF or CEP filings on record for 23 active ingredients and is linked to 3 FDA-registered manufacturing sites. 19 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “FDC Limited: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/fdc-limited

Overview

FDC Limited is a leading pharmaceutical company based in India, specializing in the development, manufacturing, and distribution of a wide range of healthcare products, including prescription pharmaceuticals, OTC (over-the-counter) medications, and food products. The company is known for its research and development capabilities and has a sustained focus on innovative therapies.

Core services & business areas

Pharmaceutical DistributionRegulatory AffairsCold Chain

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which FDC Limited holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

FDC Limited holds 17 active (29 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • BROMFENAC SODIUM HYDRATEActive2026-09-28
  • FLURBIPROFEN USP (PROCESS 3)Active2026-09-24
  • Arformoterol TartrateActive2026-03-31
  • SEMAGLUTIDEActive2026-03-31
  • NEPAFENACActive2024-10-04
  • BIMATOPROST USPActive2024-08-12
  • BRINZOLAMIDE USPActive2024-03-06
  • DORZOLAMIDE HYDROCHLORIDE USP (PROCESS II)Active2019-04-02
  • CINNARIZINEActive2017-09-07
  • OLOPATADINE HYDROCHLORIDE USPActive2015-06-23
  • LATANOPROST USPActive2010-05-18
  • BRIMONIDINE TARTRATE USPActive2007-09-17
  • ECONAZOLE NITRATE USPActive1993-08-09
  • TIMOLOL MALEATE USPActive1992-07-27
  • FLURBIPROFEN USPActive1989-09-07
  • ALBUTEROL SULFATE USPActive1988-12-12
  • MICONAZOLE NITRATE USPActive1988-03-04
  • TELMISARTAN USPInactive2017-08-01
  • MICONAZOLE USPInactive2011-04-21
  • LEVALBUTEROL HYDROCHLORIDEInactive2008-03-05
  • DORZOLAMIDE HYDROCHLORIDE USPInactive2007-09-17
  • DANTROLENE SODIUMInactive2004-05-27
  • KETOCONAZOLEInactive2003-08-27
  • FLUCONAZOLEInactive2003-06-12
  • METAXALONEInactive2003-03-04
  • MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN MAHARASHTRA STATE, INDIA.Inactive1987-08-07
  • DIAZEPAM U.S.P. XXIInactive1987-06-18
  • METRONIDAZOLE U.S.P. XXIInactive1987-06-18
  • FACILS & GEN. OPERATING PROCEDS. FOR MFGR OF BULK DRUG PRODS: W/FORMUInactive1983-05-25

Registered manufacturing sites (3)

Physical sites registered with the US FDA and resolved to FDC Limited, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

19 FDA enforcement records linked to this company.

  • recall — Class II2025-08-06

    Defective Container: spike of the cap becomes lodged in the nozzle of the product bottle.

  • recall — Class II2025-05-14

    Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

  • recall — Class II2025-03-26

    Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

  • recall — Class II2025-02-12

    Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

  • recall — Class II2025-01-15

    Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

  • recall — Class II2024-12-18

    Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

  • recall — Class II2024-11-13

    Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

  • recall — Class II2024-08-28

    Defective Container: patients are unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

  • recall — Class II2024-08-21

    Defective container; yellow colored spike from cap lodged in the nozzle

  • recall — Class II2024-08-07

    Defective container: unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

  • recall — Class II2024-05-15

    Defective Container: yellow-colored spike from cap lodged in the nozzle. Firm received several complaints from customers.

  • 4832018-08-16

    Data secured in course of each test

  • 4832018-08-16

    Absence of Written Procedures

  • 4832018-08-16

    Scientifically sound laboratory controls

  • 4832018-08-16

    Acceptance criteria for sampling & testing

  • 4832018-08-16

    Following/documenting laboratory controls

  • 4832018-08-16

    Complaint Investigation/Follow-Up Findings

  • 4832018-08-16

    Procedures for sterile drug products

  • 4832018-08-16

    Procedures not in writing, fully followed

For suppliers

Is this FDC Limited?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.